Investing to become financially independent
Investing to become financially independent
Novartis, a leader in the global pharmaceutical industry, has solid fundamentals despite stagnant profits. While the quality of its assets is undeniable, the stock currently appears overvalued, prompting investors to wait for a potential market correction before investing.
Analysis of Novartis AG (NOVN:VTX) Read More »
Discover the iShares MSCI Switzerland Capped Index ETF (EWL), an investment vehicle that offers exposure to large Swiss companies such as Nestlé, Roche and Novartis. This ETF allows you to obtain a solid dividend yield while protecting yourself against currency risks, with an excellent return-risk ratio.
iShares MSCI Switzerland Capped Index (EWL) Read More »
Discover an in-depth analysis of Swiss SMI companies that offer attractive and regular dividends for investors. The article examines in detail the performance of large companies such as Nestlé, Roche, Swisscom and Syngenta, while assessing their reliability and potential for an investment strategy based on growing dividends.
SMI and growing dividends (by Jean-Louis – guest member) Read More »
Discover the detailed analysis of Novartis, the pharmaceutical giant born from the merger of Ciba-Geigy and Sandoz, and its dividend policy that raises ethical and economic questions. Between job cuts and sustainable dividend growth, let's explore how this global leader in pharma balances its social responsibilities and financial performance.
Novartis (VTX:NOVN) Read More »
Discover Roche, the Swiss pharmaceutical giant, world leader in cancer treatment and virology, with flagship products such as Valium and Tamiflu. The group offers an attractive yield of 3.24% and a sustained growth of its dividends, making it an interesting investment despite a higher volatility than its competitors.
The portfolio is showing encouraging signs thanks to the simultaneous progress of the dollar and the market, despite remaining in the red. Strategic adjustments to the algorithm have been made to better manage currency risk, with a particular focus on stocks offering good resistance to dollar fluctuations.
Slightly better... Read More »
The merger of Ciba-Geigy and Sandoz in 1996 gave rise to Novartis, now the world's 3rd largest pharmaceutical group. Despite its relative youth, the Basel-based company presents an attractive profile for investors, with a dividend yield of 3% and steadily increasing payouts.
Novartis (VTX:NOVN) Read More »
Français 
English 
Italiano 
Deutsch 
Español 
Português